China Universal Asset Management Co. Ltd. Invests $359,000 in Indivior PLC (NASDAQ:INDV)

China Universal Asset Management Co. Ltd. bought a new stake in Indivior PLC (NASDAQ:INDV) in the 4th quarter, Holdings Channel reports. The firm bought 28,906 shares of the company’s stock, valued at approximately $359,000.

A number of other institutional investors have also added to or reduced their stakes in INDV. Iron Triangle Partners LP acquired a new position in shares of Indivior during the 3rd quarter worth about $8,243,000. Krensavage Asset Management LLC bought a new position in Indivior during the third quarter worth about $6,843,000. Stonepine Capital Management LLC acquired a new position in Indivior during the third quarter worth approximately $2,632,000. Clark Estates Inc. NY bought a new stake in Indivior in the third quarter valued at approximately $2,477,000. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Indivior in the third quarter valued at approximately $2,364,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Indivior Stock Performance

INDV opened at $11.90 on Monday. The stock has a fifty day moving average of $11.80 and a 200-day moving average of $11.05. The company has a market capitalization of $1.64 billion, a P/E ratio of -297.43 and a beta of 0.74. Indivior PLC has a fifty-two week low of $7.33 and a fifty-two week high of $23.22.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Rodman & Renshaw started coverage on Indivior in a report on Tuesday, January 28th. They set a “buy” rating and a $16.00 target price on the stock. RODMAN&RENSHAW raised shares of Indivior to a “strong-buy” rating in a research report on Tuesday, January 28th. Piper Sandler reaffirmed an “overweight” rating and set a $16.00 target price (up previously from $15.00) on shares of Indivior in a report on Friday, October 25th. Finally, Craig Hallum lowered their price target on shares of Indivior from $20.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, October 11th.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.